338 related articles for article (PubMed ID: 19458056)
1. Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure.
Woodfield GW; Hitchler MJ; Chen Y; Domann FE; Weigel RJ
Clin Cancer Res; 2009 Jun; 15(11):3672-9. PubMed ID: 19458056
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.
Kulak MV; Cyr AR; Woodfield GW; Bogachek M; Spanheimer PM; Li T; Price DH; Domann FE; Weigel RJ
Oncogene; 2013 Aug; 32(34):4043-51. PubMed ID: 22964634
[TBL] [Abstract][Full Text] [Related]
3. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
Sharma D; Blum J; Yang X; Beaulieu N; Macleod AR; Davidson NE
Mol Endocrinol; 2005 Jul; 19(7):1740-51. PubMed ID: 15746193
[TBL] [Abstract][Full Text] [Related]
4. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
Mossman D; Kim KT; Scott RJ
BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
[TBL] [Abstract][Full Text] [Related]
5. TFAP2C regulates carbonic anhydrase XII in human breast cancer.
Franke CM; Gu VW; Grimm BG; Cassady VC; White JR; Weigel RJ; Kulak MV
Oncogene; 2020 Feb; 39(6):1290-1301. PubMed ID: 31636386
[TBL] [Abstract][Full Text] [Related]
6. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
David GL; Yegnasubramanian S; Kumar A; Marchi VL; De Marzo AM; Lin X; Nelson WG
Cancer Biol Ther; 2004 Jun; 3(6):540-8. PubMed ID: 15034303
[TBL] [Abstract][Full Text] [Related]
7. Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells.
Li Y; Yuan YY; Meeran SM; Tollefsbol TO
Mol Cancer; 2010 Oct; 9():274. PubMed ID: 20946668
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
[TBL] [Abstract][Full Text] [Related]
9. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Yang X; Phillips DL; Ferguson AT; Nelson WG; Herman JG; Davidson NE
Cancer Res; 2001 Oct; 61(19):7025-9. PubMed ID: 11585728
[TBL] [Abstract][Full Text] [Related]
10. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
Xu J; Huo D; Chen Y; Nwachukwu C; Collins C; Rowell J; Slamon DJ; Olopade OI
Breast Cancer Res Treat; 2010 Apr; 120(3):593-601. PubMed ID: 19466541
[TBL] [Abstract][Full Text] [Related]
11. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
Meng CF; Zhu XJ; Peng G; Dai DQ
Oncol Rep; 2009 Nov; 22(5):1221-7. PubMed ID: 19787243
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
13. Trichostatin A and 5 Aza-2' deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR.
Pryzbylkowski P; Obajimi O; Keen JC
Breast Cancer Res Treat; 2008 Sep; 111(1):15-25. PubMed ID: 17891453
[TBL] [Abstract][Full Text] [Related]
14. Regulation of estrogen receptor β1 expression in breast cancer by epigenetic modification of the 5' regulatory region.
Al-Nakhle H; Smith L; Bell SM; Burns PA; Cummings M; Hanby AM; Lane S; Parker MD; Hughes TA; Speirs V
Int J Oncol; 2013 Dec; 43(6):2039-45. PubMed ID: 24068253
[TBL] [Abstract][Full Text] [Related]
15. Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells.
Woodfield GW; Chen Y; Bair TB; Domann FE; Weigel RJ
Genes Chromosomes Cancer; 2010 Oct; 49(10):948-62. PubMed ID: 20629094
[TBL] [Abstract][Full Text] [Related]
16. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling.
Woodfield GW; Horan AD; Chen Y; Weigel RJ
Cancer Res; 2007 Sep; 67(18):8439-43. PubMed ID: 17875680
[TBL] [Abstract][Full Text] [Related]
17. The TCF4/β-catenin pathway and chromatin structure cooperate to regulate D-glucuronyl C5-epimerase expression in breast cancer.
Mostovich LA; Prudnikova TY; Kondratov AG; Gubanova NV; Kharchenko OA; Kutsenko OS; Vavilov PV; Haraldson K; Kashuba VI; Ernberg I; Zabarovsky ER; Grigorieva EV
Epigenetics; 2012 Aug; 7(8):930-9. PubMed ID: 22805760
[TBL] [Abstract][Full Text] [Related]
18. Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.
Zhang YW; Staal B; Dykema KJ; Furge KA; Vande Woude GF
PLoS One; 2012; 7(6):e38955. PubMed ID: 22701735
[TBL] [Abstract][Full Text] [Related]
19. Re-expression of methylation-induced tumor suppressor gene silencing is associated with the state of histone modification in gastric cancer cell lines.
Meng CF; Zhu XJ; Peng G; Dai DQ
World J Gastroenterol; 2007 Dec; 13(46):6166-71. PubMed ID: 18069755
[TBL] [Abstract][Full Text] [Related]
20. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
Magdinier F; Wolffe AP
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4990-5. PubMed ID: 11309512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
